Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. (1st February 2014)
- Record Type:
- Journal Article
- Title:
- Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. (1st February 2014)
- Main Title:
- Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing
- Authors:
- Whiley, Phillip J
de la Hoya, Miguel
Thomassen, Mads
Becker, Alexandra
Brandão, Rita
Pedersen, Inge Sokilde
Montagna, Marco
Menéndez, Mireia
Quiles, Francisco
Gutiérrez-Enríquez, Sara
De Leeneer, Kim
Tenés, Anna
Montalban, Gemma
Tserpelis, Demis
Yoshimatsu, Toshio
Tirapo, Carole
Raponi, Michela
Caldes, Trinidad
Blanco, Ana
Santamariña, Marta
Guidugli, Lucia
de Garibay, Gorka Ruiz
Wong, Ming
Tancredi, Mariella
Fachal, Laura
Ding, Yuan Chun
Kruse, Torben
Lattimore, Vanessa
Kwong, Ava
Chan, Tsun Leung
Colombo, Mara
De Vecchi, Giovanni
Caligo, Maria
Baralle, Diana
Lázaro, Conxi
Couch, Fergus
Radice, Paolo
Southey, Melissa C
Neuhausen, Susan
Houdayer, Claude
Fackenthal, Jim
Hansen, Thomas Van Overeem
Vega, Ana
Diez, Orland
Blok, Rien
Claes, Kathleen
Wappenschmidt, Barbara
Walker, Logan
Spurdle, Amanda B
Brown, Melissa A
… (more) - Abstract:
- Abstract: BACKGROUND: Accurate evaluation of unclassified sequence variants in cancer predisposition genes is essential for clinical management and depends on a multifactorial analysis of clinical, genetic, pathologic, and bioinformatic variables and assays of transcript length and abundance. The integrity of assay data in turn relies on appropriate assay design, interpretation, and reporting. METHODS: We conducted a multicenter investigation to compare mRNA splicing assay protocols used by members of the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) consortium. We compared similarities and differences in results derived from analysis of a panel of breast cancer 1, early onset ( BRCA1 ) and breast cancer 2, early onset ( BRCA2 ) gene variants known to alter splicing ( BRCA1 : c.135-1G>T, c.591C>T, c.594-2A>C, c.671-2A>G, and c.5467+5G>C and BRCA2 : c.426-12_8delGTTTT, c.7988A>T, c.8632+1G>A, and c.9501+3A>T). Differences in protocols were then assessed to determine which elements were critical in reliable assay design. RESULTS: PCR primer design strategies, PCR conditions, and product detection methods, combined with a prior knowledge of expected alternative transcripts, were the key factors for accurate splicing assay results. For example, because of the position of primers and PCR extension times, several isoforms associated with BRCA1, c.594-2A>C and c.671-2A>G, were not detected by many sites. Variation was most evident for theAbstract: BACKGROUND: Accurate evaluation of unclassified sequence variants in cancer predisposition genes is essential for clinical management and depends on a multifactorial analysis of clinical, genetic, pathologic, and bioinformatic variables and assays of transcript length and abundance. The integrity of assay data in turn relies on appropriate assay design, interpretation, and reporting. METHODS: We conducted a multicenter investigation to compare mRNA splicing assay protocols used by members of the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) consortium. We compared similarities and differences in results derived from analysis of a panel of breast cancer 1, early onset ( BRCA1 ) and breast cancer 2, early onset ( BRCA2 ) gene variants known to alter splicing ( BRCA1 : c.135-1G>T, c.591C>T, c.594-2A>C, c.671-2A>G, and c.5467+5G>C and BRCA2 : c.426-12_8delGTTTT, c.7988A>T, c.8632+1G>A, and c.9501+3A>T). Differences in protocols were then assessed to determine which elements were critical in reliable assay design. RESULTS: PCR primer design strategies, PCR conditions, and product detection methods, combined with a prior knowledge of expected alternative transcripts, were the key factors for accurate splicing assay results. For example, because of the position of primers and PCR extension times, several isoforms associated with BRCA1, c.594-2A>C and c.671-2A>G, were not detected by many sites. Variation was most evident for the detection of low-abundance transcripts (e.g., BRCA2 c.8632+1G>A Δ19, 20 and BRCA1 c.135-1G>T Δ5q and Δ3). Detection of low-abundance transcripts was sometimes addressed by using more analytically sensitive detection methods (e.g., BRCA2 c.426-12_8delGTTTT ins18bp). CONCLUSIONS: We provide recommendations for best practice and raise key issues to consider when designing mRNA assays for evaluation of unclassified sequence variants. … (more)
- Is Part Of:
- Clinical chemistry. Volume 60:Number 2(2014)
- Journal:
- Clinical chemistry
- Issue:
- Volume 60:Number 2(2014)
- Issue Display:
- Volume 60, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 60
- Issue:
- 2
- Issue Sort Value:
- 2014-0060-0002-0000
- Page Start:
- 341
- Page End:
- 352
- Publication Date:
- 2014-02-01
- Subjects:
- Clinical chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
Biochemistry -- Periodicals
Biochimie -- Périodiques
Diagnostics biologiques -- Périodiques
Biochemistry
Clinical chemistry
Pharmaceutical chemistry
Biochemistry
Laboratory Techniques and Procedures
Klinische chemie
Periodicals
616.075605 - Journal URLs:
- http://www.oxfordjournals.org/ ↗
https://academic.oup.com/clinchem ↗
http://catalog.hathitrust.org/api/volumes/oclc/1554929.html ↗
http://www.clinchem.org/ ↗ - DOI:
- 10.1373/clinchem.2013.210658 ↗
- Languages:
- English
- ISSNs:
- 0009-9147
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15282.xml